Digene launches HBV (hepatitis B virus) test for research use:
This article was originally published in Clinica
Digene has launched a DNA test for hepatitis B based on its Hybrid Capture technology for use in measuring the effects of antiviral therapies in US patients. HBV is the second most common chronic infectious disease in the world, affecting 350 million people and killing one million every year. The test, which is already used outside the US, detects the virus and measures viral load in response to therapy. Use in the US will be limited to drug research until the FDA has cleared it for clinical use.
You may also be interested in...
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.
Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.